Velox Cap 40 mg (Fexuprazan Hydrochloride)

Adult dose

This medicine is administered to adults as follows. 1. Treatment of erosive gastroesophageal reflux disease - Administer 40mg orally once daily for 4 weeks. - If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. This medicine may be taken with or without food.

This medicine should not be administered to certain patients. First, individuals who are allergic to this medicine or have previously experienced hypersensitivity reactions should not use it. Also, patients taking medications that include Atazanavir, Nelfinavir, or Rilpivirine should not take this medicine concurrently. Women who are pregnant or breastfeeding should not take this medicine, and extra caution is required during pregnancy. This medicine contains lactose, so patients with lactose intolerance or certain genetic conditions should not take it. Patients with liver or kidney dysfunction do not have enough experience with this medicine, so it must be administered carefully. Elderly individuals may have diminished bodily functions and should use it cautiously. Individuals who have allergic reactions to Tartrazine (Yellow No. 5), one of the components of this medicine, should exercise particular caution. When taking this medicine, gastrointestinal disturbances, headaches, and skin rashes may occur. Rarely, various abnormal reactions such as dizziness, myalgia, fever, and allergic symptoms have been reported, so if symptoms are severe, consult a physician. This medicine can reduce stomach acid, which may promote bacterial growth in the gastrointestinal tract, slightly increasing the risk of gastrointestinal infections. Furthermore, long-term high-dose use may increase the risk of osteoporosis-related fractures, so patients at risk of fractures should undergo regular testing. Prolonged use for more than three months may lead to decreased blood magnesium levels, thus regular testing is necessary. This medicine can alter gastric acidity, affecting the absorption of other drugs, so caution is needed when used with certain medications. In particular, taking it with Atazanavir or Nelfinavir may reduce the effectiveness of this medicine. It is safer for women who are pregnant or breastfeeding not to take this medicine, and breastfeeding should be discontinued if it is used. Safety and efficacy in pediatric and adolescent populations have not been sufficiently evaluated, so its use is not recommended. No serious side effects have been reported with overdose; however, if overdose is suspected, inform medical personnel immediately and receive appropriate treatment. Finally, this medicine should be stored out of the reach of children, and transferring it to another container is not advisable for maintaining quality.

• Dyspepsia
• diarrhea
• nausea
• abdominal discomfort
• chronic gastritis
• gastritis
• erosive gastritis
• erythema
• pruritus
• headache

This medicine should be stored in a tightly closed container to prevent exposure to air and moisture, and it is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. Storing it this way can help preserve its effectiveness for a longer period.

Appearance

Light green, oblong film-coated tablet

Package unit

28 tablets/box [7 tablets/PTP*4], 56 tablets/box [7 tablets/PTP*8], 100 tablets/bottle, 28 tablets/bottle, 300 tablets/bottle